Dasatinib, a Kinase Inhibitor to Treat Chronic Myelogenous Leukemia

Analogue-Based Drug Discovery II

Volumn , Issue , 2010, Pages 493-506

  Das, Jagabandhu ^a   Barrish, Joel C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Bcr Abl kinase; Chronic myelogenous leukemia; Cytogenetic response; Hematologic response; Imatinib resistance; Oral bioavailability; Thiazole ring

Indexed keywords

EID: 84863729689     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630035.ch20     Document Type: Chapter

References (36)

1. Cohen, P. (2002) Protein kinases: the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 1, 309-315.
2. Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science, 298, 1912-1934.
3. Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., Zimmermann, J., and Lyndon, N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2, 561-566.
4. Schiffer, C.A. (2007) BCRABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med., 357, 258-265.
5. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., and Druker, B. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346, 645-652.
6. Drucker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W.N., Silver, R.T., Goldman, J.M., Stone, R.M., Cervantes, N., Hochhaus, A., Powell, B.L., Gabrilove, J.L., Rousselot, P., Reiffers, J., Cornelissen, J.J., Hughs, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J.L., Radich, J.P., Simonsson, B., Taylor, K., Baccarani, J.P., So, C., Letvak, L., and Larson, R. (2006) Five year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 355, 2408-2417.
7. Lahaye, T., Riehm, B., Berger, U., Paschka, P., Muller, M.C., Kreil, S., Merx, K., Schwindel, U., Schoch, C.,Hehlmann, R., and Hochhaus, A. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 103, 1659-1669.
8. Daub, H., Specht, K., and Ullrich, A. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov., 3, 1001-1010.
9. Weisberg, E. and Griffen, J.D. (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist. Updates, 6, 231-238.
10. O'Hare, T., Corbin, A.S., and Druker, B.J. (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev., 16, 92-99.
11. Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Brissette, W.H., Weringer, E.J., Pollok, B.A., and Connelly, P.A. (1996) Discovery of a novel, potent, and Src-selective tyrosine kinase inhibitor. Study of Lck- and Fyn T-dependent T cell activation. J. Biol. Chem., 271, 695-701.
12. Molina, T.J., Kishihara, K., Siderovski, D.P., van Ewijk, W., Narendran, A., Timms, E.,Wakeham, A., Paige, C.J., Hartman, K.-U., Veilette, A., Davison, D., and Mak, T.W. (1992) Profound block in thymocyte development in mice lacking p56lck. Nature, 357, 161-164.
13. Chan, A.C., Desai, D.M., and Weiss, A.C. (1994) The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Ann. Rev. Immunol., 12, 555-592.
14. Kamens, J.S., Ratnofsky, S.E., and Hirst, G.C. (2001) Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. Curr. Opin. Invest. Drugs, 2, 1213-1219.
15. Susa, M. and Teti, A. (2000) Tyrosine kinase src inhibitors: potential therapeutic applications. Drug News Perspect., 13, 169-175.
16. Wityak, J., Das, J., Moquin, R.V., Shen, Z., Lin, J., Chen, P., Doweyko, A.M., Pitt, S., Pang, S., Shen, D.R., Fang, Q., de Fex, H.F., Schieven, G.L., Kanner, S.B., and Barrish, J.C. (2003) Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinsae p56lck. Bioorg. Med. Chem. Lett., 13, 4007-4010.
17. Snow, R.J., Cardozo, M.G., Morwick, T.M., Busacca, C.A., Dong, Y., Eckner, R.J., Jacober, S., Jakes, S., Kapadia, S., Lukas, S., Panzenbeck, M., Peet, G.W., Peterson, J.D., Prokopowicz, A.S., III, Sellati, R., Tolbert, R.M., Tschantz, M.A., and Moss, N. (2002) Discovery of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of Lck kinase. J. Med. Chem., 45, 3394-3405.
18. Chen, P., Doweyko, A.M., Norris, D., Gu, H.H., Spergel, S.H., Das, J., Moquin, R.V., Lin, J., Wityak, J., Iwanowicz, E.J., McIntyre, K.W., Shuster, D.J., Behnia, K., Chong, S., deFex, H., Pang, S., Pitt, S., Shen, D.R., Thrall, S., Stanley, P., Kocy, O.R., Witmer, M.R., Kanner, S.B., Schieven, G.L., and Barrish, J.C. (2004) Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo[1,5-a] pyrido[3,2-e] pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo anti-inflammatory activity. J. Med. Chem., 47, 4517-4529.
19. Das, J., Lin, J., Moquin, R.V., Shen, Z., Spergel, S.H., Wityak, J., Doweyko, A.M., deFex, H.R., Fang, Q., Pang, S., Pitt, S., Shen, D.R., Schieven, G.L., and Barrish, J.C. (2003) Molecular design, synthesis and structure activity relationships leading to the potent and selective p56lck inhibitor BMS-243117. Bioorg. Med. Chem. Lett., 13, 2145-2149.
20. Das, J., Moquin, R.V., Lin, J., Liu, C., Doweyko, A.M., deFex, H.R., Fang, Q., Pang, S., Pitt, S., Shen, D.R., Schieven, G.L., Barrish, J.C., and Wityak, J. (2003) Discovery of 2-amino-heteroarylbenzothiazole-6-anilides as potent p56lck inhibitors. Bioorg. Med. Chem. Lett., 13, 2587-2590.
21. Chen, P., Norris, D., Das, J., Spergel, S.H., Wityak, J., Leith, L., Zhao, R., Chen, B.-C., Pitt, S., Pang, S., Shen, D.R., Zhang, R., deFex, H.R., Doweyko, A.M., McIntyre, K.W., Shuster, D.J., Behnia, K., Schieven, G., and Barrish, J. (2004) Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56lck inhibitors. Bioorg. Med. Chem. Lett., 143, 6061-6066.
22. Das, J., Chen, P., Norris, D., Padmanabha, R., Lin, J., Moquin, R.V., Shen, Z., Cook, L.S., Doweyko, A.M., Pitt, S., Pang, S., Shen, D.R., Fang, Q., de Fex, H.F., McIntyre, K.W., Shuster, D.J., Gillooly, K.M., Behnia, K., Schieven, G.L., Wityak, J., and Barrish, J.C. (2006) 2-Aminothiazole as a novel kinase inhibitor template. Structure activity relationship studies towards the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-m ethyl-4-pyrimidinyl] amino]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem., 49, 6819-6832.
23. Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barrish, J.C., Behnia, K.,Castaneda, S., Cornelius, L., Das, J., Doweyko, A.M., Fairchild, C., Hunt, J.T., Inigo, I., Kamath, A., Kan, D.,Marathe, P., Pang, S., Pitt, S., Schieven, G.L., Schmidt, R.J., Tokarski, J., Wen, M.-L., Wityak, J., and Borzilleri, R.M. (2004) Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-me thylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/ Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem., 47, 6658-6661.
24. Kamath, A.V., Wang, J., Lee, F.Y., and Marathe, P.H. (2008) Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor Src and Bcr-Abl. Cancer Chemother. Pharmacol., 61, 365-376.
25. Tokarski, J.S., Newitt, J.A., Chang, C.Y.J., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y.F., Borzilleri, R., Lombardo, L.J., Xie, D., Zhang, Y., and Klei, H.E. (2006) The structure of dasatinib (BMS-354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Res., 66, 5790-5797.
26. Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller, W.T., Clarkson, B., andKuriyan, J. (2002)Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 62, 4236-4243.
27. O'Hare, T.,Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W.N., and Druker, B.J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res., 65, 4500-4505.
28. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., and Sawyers, C.L. (2005) Overriding imatinib resistance with a novel Abl kinase inhibitor. Science, 305, 399-401.
29. Moshe, T., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.-T., Huang, F., Decillis, A.P., and Sawyers, C.L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 354, 2531-2541.
30. Hochhaus, A., Kantarjian, H.M., Baccarani, M., Lipton, J.H., Apperley, J.F., Druker, B.J., Facon, T., Goldberg, S.L., Cervantes, F., Niederwieser, D., Silver, R.T., Stone, R.M., Hughes, T.P., Muller, M.C., Ezzeddine, R., Countouriotis, A.M., and Shah, N.P. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109, 2303-2309.
31. Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E.O., Baccarani, M., Roboz, G.J., Amadori, S., de Souza, C.A., Lipton, J.H., Hochhaus, A., Heim, D., Larson, R.A., Branford, S., Muller, M.C., Agarwal, P., Gollerkeri, A., and Talpaz, M. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, 4143-4150.
32. Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A., and Baccarani, M. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, 3207-3213.
33. Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., Hellmann, A., Zaritsky, A., Golenkov, A., Radich, J., Hughes, T., Countouriotis, A., and Shah, N. (2007) Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood, 109, 5143-5150.
34. Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P.P., Palandri, F., Giannoulia, P., Marzocchi, G., Luatti, S., Testoni, N., Iacobucci, I., Cilloni, D., Saglio, G., Baccarani, M., and Martinelli, G. (2007) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 92, 401-404.
35. Finn, R.S., Dering, J., Ginther, C., Wilson, C.A., Glaspy, P., Tchekmedyian, N., and Slamon, D.J. (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat., 105, 319-326.
36. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T.W., Lee, F., Shaw, P., and Clark, E. (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res., 67, 2226-2238.